Johnson & Johnson (NYSE:JNJ) Stock Jumps 2% - What's Next?

Key Points

• Johnson & Johnson shares rose 2% to about $281.86, while trading volume was 13% below its average.
• The company reported encouraging pipeline updates: ICOTYDE met its primary endpoint in a Phase 3 psoriatic arthritis trial, and an investigational prostate cancer combination showed early PSA reductions, with J&J planning to advance it to Phase 3.
• J&J’s latest quarterly results modestly beat estimates, with earnings of $2.59 per share and revenue of $25.40 billion; analysts have a “Moderate Buy” consensus rating and an average price target of $275.92.

Johnson & Johnson (NYSE:JNJ - Get Free Report) rose 2% on Monday. The company traded as high as $282.73 and last traded at $281.8640. Approximately 6,897,281 shares changed hands during trading, a decline of 13% from the average session volume of 7,970,804 shares. The stock had previously closed at $276.22.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Investigational drug ICOTYDE (icotrokinra) met the primary endpoint in a Phase 3 trial in biologic-naive adults with psoriatic arthritis, adding a late-stage potential growth opportunity to J&J’s immunology pipeline. Article: Johnson & Johnson Showcases Positive Trial Data For Key Autoimmune Therapies
• Positive Sentiment: A first-in-human Phase 1 study of pasritamig plus JNJ-9401 reported PSA reductions of at least 50% in 11 of 15 patients at the recommended regimen; nearly half had reductions of at least 90%. The early signal and reported safety profile are encouraging, and J&J plans to advance the combination to Phase 3. Article: Johnson & Johnson reports 73% PSA response rate
• Positive Sentiment: J&J also presented new nipocalimab data in Sjögren’s disease, including findings on symptom improvements patients value. Alongside the ICOTYDE results, the updates showcase activity across its autoimmune pipeline, though the Sjögren’s findings are from Phase 2. Article: Nipocalimab Phase 2 Sjögren’s disease data
• Negative Sentiment: One report said ETFs were net sellers of J&J shares on Nov. 5, with net sales of $68.4 million. This is a potential technical headwind, but it reflects an earlier trading session and does not establish the reason for the current move. Article: ETFs Are Net Sellers of Johnson & Johnson

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on JNJ. Wells Fargo & Company upped their price objective on Johnson & Johnson from $275.00 to $287.00 and gave the company an "overweight" rating in a research report on Friday, October 16th. Raymond James Financial set a $280.00 target price on shares of Johnson & Johnson in a research report on Monday, August 3rd. HSBC upped their price target on Johnson & Johnson from $290.00 to $320.00 and gave the stock a "buy" rating in a research report on Thursday, September 10th. Freedom Capital raised Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. Finally, Stifel Nicolaus set a $260.00 price objective on Johnson & Johnson in a research note on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $275.92.

Johnson & Johnson Stock Up 2.0%

The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The company has a fifty day moving average price of $265.91 and a 200-day moving average price of $248.30. The stock has a market capitalization of $678.53 billion, a P/E ratio of 42.71, a PEG ratio of 2.73 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts' consensus estimates of $2.53 by $0.06. The company had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm's revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the company earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, research analysts forecast that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson's payout ratio is currently 81.21%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares in the company, valued at $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares of the company's stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.16% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in JNJ. National Pension Service raised its stake in shares of Johnson & Johnson by 1.3% in the second quarter. National Pension Service now owns 5,226,968 shares of the company's stock valued at $1,327,493,000 after acquiring an additional 67,484 shares during the last quarter. IFP Advisors Inc grew its position in Johnson & Johnson by 8.8% during the 2nd quarter. IFP Advisors Inc now owns 38,760 shares of the company's stock worth $9,844,000 after acquiring an additional 3,133 shares during the last quarter. Elefante Mark B increased its holdings in Johnson & Johnson by 9.8% during the 2nd quarter. Elefante Mark B now owns 28,686 shares of the company's stock valued at $7,285,000 after purchasing an additional 2,563 shares in the last quarter. AMG Asset Management Group Inc. increased its holdings in Johnson & Johnson by 172.0% during the 3rd quarter. AMG Asset Management Group Inc. now owns 3,852 shares of the company's stock valued at $1,020,000 after purchasing an additional 2,436 shares in the last quarter. Finally, Gradient Investments LLC raised its position in Johnson & Johnson by 9.9% in the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company's stock valued at $38,815,000 after purchasing an additional 13,737 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.